US Airways Is on a ...
Health Care: Drugs
Synageva BioPharma Corp (GEVA: NASDAQ)
$39.52 0.73 | 1.88%
05/21/13 - 04:00 PM ET
Latest Dividend:5.00
Latest Dividend Yield:0.00%
Dividend Ex-Date:12/30/08
Price Earnings Ratio:97.38
Price Earnings Comparisons:
| GEVA | Sector Avg. | S&P 500 |
|---|---|---|
| 97.38 | 0.00 | 17.70 |
Price Performance History (% change):
| 3 Mo | 1 Yr | 3 Yr |
|---|---|---|
| 123.05 | 1386.11 | 2715.79 |
| GROWTH | 12 Mo | 3 Yr | CAGR |
|---|---|---|---|
| Revenue | 612.50 | -0.01 | 0.00 |
| Net Income | 0.00 | 0.00 | |
| EPS | -1.69 | 0.00 |
Earnings for GEVA:
| EBITDA | -39.00 |
| REVENUE | 14.95M |
Average Earnings Estimates
| Qtr (06/13) | Qtr (09/13) | FY (12/13) | FY (12/14) | |
|---|---|---|---|---|
| Average Estimate | $-0.75 | $-0.89 | $-3.16 | $-3.97 |
| Number of Analysts | 4 | 4 | 5 | 5 |
| High Estimate | $-0.68 | $-0.85 | $-3.03 | $-2.97 |
| Low Estimate | $-0.78 | $-0.93 | $-3.30 | $-4.94 |
| Prior Year | $-0.45 | $-0.43 | $-1.90 | $-3.16 |
| Growth Rate (Year over Year) | -65.56% | -106.40% | -66.53% | -25.35% |
Portfolios with GEVA
- Portfolio NameUser Type
- ContributorStocks With Big Insider Buy...
- ContributorStocks With Big Insider Buy...
- ContributorStocks With Big Insider Buy...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks At New 52-Week Highs...
- ContributorStocks At New 52-Week Highs...
Latest GEVA Headlines from TheStreet
- Synageva BioPharma Corp Enters Oversold Territory (GEVA) 05.10.13 | 12:05 pm
- GEVA Crosses Below Key Moving Average Level 05.01.13 | 11:05 am
- Top Insider Trades: AEGR GEVA DRI HNSN 01.16.13 | 09:01 am
- 5 Stocks Insiders are Scooping Up 01.09.13 | 12:01 pm
- Top Insider Trades: NCR PLCE GEVA LEI 01.09.13 | 09:01 am
- 5 Stocks Insiders Love Right Now 07.18.12 | 10:07 am
- Insiders Trading GEVA, GNOM, VPRT, HSON 07.16.12 | 09:07 am
- Insiders Trading DNKN, GEVA, HMPR, PGCG 06.29.12 | 09:06 am
- Biotech Stock Mailbag: Exelixis, Protalix, Arena 05.04.12 | 07:05 am
- 8 Stocks Rising on Monster Volume 02.29.12 | 03:02 pm
Press Releases for GEVA
- Late Onset LAL Deficiency (CESD) Literature Review Published In The Journal Of Hepatology - Business Wire 03.26.13 | 07:03 am
- Synageva BioPharma™ Reports 2012 Full Year Financial Results - Business Wire 03.11.13 | 04:03 pm
- Synageva BioPharma™ To Host 2012 Fourth Quarter And Full Year Financial Results Conference Call On March 11 - Business Wire 03.01.13 | 12:03 pm
- Synageva BioPharma™ Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2013 - Business Wire 02.28.13 | 06:02 am
- Synageva BioPharma™ To Present At The Cowen And Company 33rd Annual Health Care Conference - Business Wire 02.26.13 | 11:02 am
- Synageva BioPharma™ Initiates Dosing In Phase 3 Trial Of Sebelipase Alfa In Children And Adults With Late Onset LAL Deficiency - Business Wire 02.11.13 | 07:02 am
- Synageva BioPharma™ To Present At The Leerink Swann Global Healthcare Conference 2013 - Business Wire 02.06.13 | 04:02 pm
- Hepatology Publishes 12-Week Phase I/II Extension Study Data Of Sebelipase Alfa In Adults With Late Onset LAL Deficiency - Business Wire 02.04.13 | 04:02 pm
- Synageva BioPharma™ Highlights Data Presentations At The 9th Annual Lysosomal Disease Network (LDN) WORLD Symposium - Business Wire 01.30.13 | 04:01 pm
- Synageva BioPharma Announces Closing Of Public Offering And Exercise Of Option To Purchase Additional Shares - Business Wire 01.09.13 | 09:01 am
Partner Headlines for GEVA
- UPDATE: Piper Jaffray Lifts Synageva PT on Attractive Upcoming LAL-D Treatment - Benzinga 03.12.13 | 09:03 am
- UPDATE: Wedbush Securities Reiterates Outperform Rating, Raises PT on Synageva BioPharma Corp. - Benzinga 11.07.12 | 08:11 am
- Winning Trades Based on Analyst Ratings for June 25 - Benzinga 06.25.12 | 01:06 pm
- UPDATE: Morgan Stanley Initiates Synageva Biopharma with Buy, $76 PT - Benzinga 04.20.12 | 09:04 am
